Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a predominant cause of liver disease globally, primarily due to the rising prevalence of metabolic disorders, including obesity and diabetes. The advancement of MASLD from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis involves intricate metabolic and immune interactions. Hypoxia-Inducible Factors (HIFs) are integral to the regulation of cellular responses under hypoxic conditions, significantly influencing metabolic homeostasis and modulating immune cell functions. Within the framework of MASLD, HIFs facilitate the adaptive responses to hypoxic conditions and oxidative stress, which are pivotal drivers of disease progression. However, the precise mechanisms by which HIFs influence MASLD pathogenesis remain incompletely understood. This study seeks to investigate the role of HIFs in the immunometabolic processes of MASLD, with particular emphasis on the molecular pathways they regulate within hepatic cells and the immune microenvironment. Furthermore, we examine the challenges associated with therapeutically targeting HIFs, such as the intricate regulation of HIFs, their tissue-specific effects, and the potential risk of inducing tumorigenesis. In conclusion, we underscore prospective research avenues that may yield innovative therapeutic strategies aimed at targeting HIFs to alleviate inflammation, fibrosis, and metabolic dysregulation in MASLD.
fibrosishypoxiahypoxia-inducible factorsimmunometabolismlipid metabolismliver inflammationMASLDtherapeutic targetingThe author(s) declared that financial support was not received for this work and/or its publication.section-at-acceptanceMetabolic PhysiologyIntroduction
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as nonalcoholic fatty liver disease (NAFLD), has emerged as a significant global health issue, largely attributable to the rising incidence of obesity, diabetes, and metabolic syndrome (Chrysavgis et al., 2022; Zhong et al., 2024). This condition is characterized by the excessive accumulation of fat in the liver, occurring independently of significant alcohol intake, and can progress from simple hepatic steatosis to more severe stages, including metabolic dysfunction-associated steatohepatitis (MASH, previously known as non-alcoholic steatohepatitis or NASH), liver fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma (HCC) (Wang et al., 2025; Powell et al., 2021; Danford et al., 2018). The worldwide prevalence of MASLD has reached concerning proportions, with estimates indicating that it affects approximately 25% of the global population (Powell et al., 2021). In Europe, the prevalence is estimated to range between 20% and 40% (Cianci et al., 2022). With the rise of MASLD and its risk of progressing to a severe liver condition, MASLD is now a key focus in clinical and research areas (Kempiński et al., 2019).
In this context, “Immunometabolism” pertains to the manner in which metabolic alterations, including those mediated by hypoxia-inducible factors (HIF), directly modulate immune cell functions, thereby impacting inflammation and fibrosis in MASLD (Del Río-Moreno et al., 2019). MASLD’s pathogenesis is complex, involving metabolic and immune issues (Shin et al., 2022). Recently, HIFs, which manage cellular responses to low oxygen, have become a focus in liver diseases like MASLD (Holzner and Murray, 2021). These transcription factors control genes related to oxygen balance, metabolism, cell survival, and immunity, activating under hypoxia to help cells adapt (Liu et al., 2020). When the liver is metabolically active and subjected to uneven blood supply or low-oxygen conditions, it frequently undergoes hypoxic stress (Han et al., 2019). As MASLD progresses, hypoxia worsens because of fat buildup, increased metabolic needs, and inflammation (Han et al., 2019; Isaza et al., 2020). HIFs are key in adjusting metabolism, promoting lipid storage, regulating inflammation, and activating hepatic stellate cells, leading to fibrosis (Han et al., 2019; Chen et al., 2019a). They also affect immune cells, driving the chronic inflammation and fibrosis seen in MASH (Wang et al., 2019).
Despite substantial progress in elucidating the role of HIFs in liver pathophysiology, their exact function in the immunometabolic processes of MASLD is not yet fully understood. In particular, further research is needed to clarify how HIFs influence the intricate interplay between metabolic and immune pathways during the progression of MASLD.
Introduce the four main questions that will steer the upcoming sections:
How do HIFs contribute to the inflammatory and metabolic changes in MASLD?
What is the crosstalk between HIFs and immune cells in the liver in the context of MASLD?
How do HIFs regulate lipid metabolism and fibrosis progression in MASLD?
What are the potential therapeutic strategies targeting HIFs in the treatment of MASLD?
Figure 1 delineates the multifaceted role of HIFs in the immunometabolic processes of MASLD, highlighting their influence on hepatic metabolism and immune regulation. It also addresses the challenges associated with the therapeutic targeting of HIFs and proposes directions for future research in this evolving field.
The Role of Hypoxia-Inducible Factors in the Immunometabolism of MASLD. Within the hypoxic microenvironment characteristic of MASLD, HIFs orchestrate crucial metabolic reprogramming. This reprogramming involves redirecting hepatocyte metabolism towards steatosis, while simultaneously facilitating inflammation and fibrosis. Targeting this pathway is challenging due to dysregulated immunometabolic interactions, isoform-specific issues, and major translational hurdles. Future research should focus on creating precise delivery systems and non-invasive biomarkers, validated with advanced preclinical models like humanized mice and liver organoids, to effectively address inflammation and restore metabolic balance.
Infographic illustrating hypoxia-induced HIFs in MASLD, detailing metabolic and immune responses in hepatocytes, challenges like dysregulated immunometabolic crosstalk and lack of targeted therapies, and future research directions including precision delivery, inflammation resolution, biomarkers, and preclinical models.The mechanisms of hypoxia in MASLD and the role of HIFs
Hypoxia is a critical factor in the progression of MASLD, as insufficient oxygen supply in the liver initiates adaptive responses mediated by HIFs (Holzner and Murray, 2021). As MASLD progresses, the accumulation of lipids and the development of insulin resistance intensify hypoxic stress (Holzner and Murray, 2021). HIFs, particularly HIF-1α, modulate metabolic pathways and immune cell functions, thereby promoting inflammation and fibrosis (Liu et al., 2020). This section examines the impact of hypoxia and HIF activation on metabolic and immune processes in MASLD, elucidating their contribution to the disease’s progression from steatosis to more advanced stages, such as MASH and fibrosis.
Mechanisms of hypoxia and activation of HIFs in MASLD
MASLD is closely associated with a disrupted hepatic microenvironment characterized by metabolic disturbances and immune cell infiltration (Zuo et al., 2025). One critical factor contributing to the progression of MASLD is hypoxia, which occurs due to an imbalance between oxygen supply and demand (Han et al., 2019; van der Graaff et al., 2019). As the disease progresses, excessive lipid accumulation in hepatocytes leads to increased oxygen consumption, while the liver’s blood supply becomes insufficient to meet this demand, thereby creating localized hypoxic conditions (Han et al., 2019; van der Graaff et al., 2019; Sundaram et al., 2016).
Hypoxia in the liver activates HIFs, a family of transcription factors that play a central role in the cellular response to low oxygen levels (Tirosh, 2018). HIFs are composed of an oxygen-sensitive α subunit (HIF-1α, HIF-2α, and HIF-3α) and a constitutively expressed β subunit (HIF-1β) (Yan et al., 2024; He Y. et al., 2021). Under normal oxygen conditions, HIF-α subunits are hydroxylated by prolyl hydroxylases (PHDs), leading to their degradation by the von Hippel-Lindau (VHL) complex (Han et al., 2021; Dong et al., 2017). However, in hypoxic conditions, the hydroxylation of HIF-α subunits is inhibited, stabilizing them and allowing them to translocate into the nucleus (Riopel et al., 2020). Once in the nucleus, HIFs bind to hypoxia response elements (HREs) in the promoter regions of target genes, driving the transcription of genes involved in various adaptive responses, including angiogenesis, glycolysis, erythropoiesis, and immune modulation (Tirosh, 2018; Davis et al., 2022; Orlando et al., 2020).
In MASLD, hypoxia predominantly results from the expansion of adipose tissue, the accumulation of lipids within hepatocytes, and heightened metabolic demands, especially in the context of obesity and insulin resistance (Han et al., 2019). The hepatic microvascular alterations observed in MASLD, including endothelial dysfunction and capillary rarefaction, intensify this hypoxic condition, thereby further activating HIFs and their associated downstream signaling pathways (Asai et al., 2017; Vita et al., 2019). HIF-1α is the most extensively investigated isoform in the context of liver diseases, including MASLD, due to its pivotal role in modulating metabolic pathways under hypoxic conditions (He Y. et al., 2021; Luo et al., 2023). In hepatocytes, the activation of HIF-1α facilitates glycolysis and fatty acid synthesis, processes essential for sustaining cellular energy homeostasis during hypoxia (Luo et al., 2023; Lefere et al., 2016). Moreover, HIF-1α upregulates the expression of genes associated with lipid storage, such as those encoding enzymes like fatty acid synthase (FASN) and sterol regulatory element-binding protein 1 (SREBP-1c), which are integral to the pathogenesis of hepatic steatosis (Ezzeddini et al., 2019; Yin G. et al., 2025).
The role of HIF-1α in hepatic lipid metabolism is also linked to its regulation of inflammation and fibrosis in MASLD (Holzner and Murray, 2021; Wang et al., 2019; Luo et al., 2023). In the hypoxic liver, HIF-1α mediates the activation of hepatic stellate cells (HSCs), which are pivotal in the development of liver fibrosis (Kou et al., 2023; Li et al., 2016). Under hypoxic conditions, HIF-1α upregulates the expression of pro-fibrotic factors such as transforming growth factor-beta (TGF-β) and collagen, leading to ECM deposition and fibrosis progression (Kou et al., 2023; Li Y. et al., 2025; Packer, 2020). In addition to metabolic and fibrotic changes, hypoxia-driven activation of HIFs also impacts immune cell function in the liver (Wang et al., 2019). Hypoxic stress influences the polarization of macrophages, promoting a pro-inflammatory M1 phenotype that exacerbates inflammation in MASLD (Wang et al., 2019; Zhu et al., 2021; Wang et al., 2021). The activation of HIF-1α in macrophages induces the expression of key inflammatory cytokines, including TNF-α, IL-6, and IL-1β, which contribute to the chronic low-grade inflammation observed in MASH and fibrosis (see Figure 2) (Mesarwi et al., 2021).
The Mechanisms of HIF Activation driving MASLD Progression. (A) Normoxic Conditions: In healthy hepatocytes with adequate oxygen, HIF-α subunits are constantly hydroxylated by PHDs, recognized by VHL, and targeted for proteasomal degradation, preventing transcriptional activity. (B) Hypoxic Conditions: Under conditions of hypoxia characteristic of MASLD, PHDs are inhibited. HIF-α stabilizes, translocates to the nucleus, dimerizes with HIF-β, and binds to Hypoxia Response Elements (HREs) to initiate gene transcription. (C) Downstream Pathological Pathways: HIF activation drives MASLD progression through two major axes. Metabolically, it upregulates glycolysis and de novo lipogenesis genes (SREBP-1c, FASN), leading to steatosis and promoting insulin resistance. Immunologically, it induces pro-inflammatory cytokines (TNF-α, IL-6) which, along with direct signals, activate Hepatic Stellate Cells (HSCs), leading to TGF-β production, collagen deposition, and liver fibrosis.
Diagram explaining HIF-1α regulation in liver cells under normoxic (left) and hypoxic (right) conditions, showing downstream effects on metabolic dysregulation, steatosis, inflammation, hepatic stellate cell activation, and fibrosis relevant to MASLD pathology.Metabolic and immune modulation by HIFs in MASLD
In the hypoxic liver, HIFs orchestrate a range of metabolic adaptations to sustain cellular energy homeostasis (Cui et al., 2023). Notably, HIF-1α plays a pivotal role in modulating glucose and lipid metabolism under conditions of reduced oxygen availability (Luo et al., 2023; Yi et al., 2022). Under normoxic conditions, the liver predominantly utilizes oxidative phosphorylation for energy production (Chen et al., 2022; Basheeruddin and Qausain, 2024). However, during hypoxia, HIF-1α activates alternative metabolic pathways that promote anaerobic metabolism (Yi et al., 2022). A critical metabolic adaptation in response to HIF activation is the upregulation of glycolysis (Yi et al., 2022; Xiong et al., 2025). HIF-1α enhances the expression of glycolytic enzymes, such as glucose transporter 1 (GLUT1) and hexokinase, facilitating increased glucose uptake and its conversion to lactate by hepatocytes, even in the absence of adequate oxygen (Xiong et al., 2025). This shift towards glycolysis is particularly pertinent in the context of MASLD, where insulin resistance frequently leads to compromised glucose utilization, thereby exacerbating hepatic steatosis (He Y. et al., 2021). In addition to its role in promoting glycolysis, HIF-1α plays a significant role in lipid metabolism, a critical process in the pathogenesis of hepatic steatosis associated with MASLD (Luo et al., 2023; Cui et al., 2023). HIF-1α upregulates the expression of SREBP-1c, a pivotal transcription factor that governs lipid synthesis and storage (Ezzeddini et al., 2019; Mesquita et al., 2020). Through the activation of genes involved in fatty acid synthesis, such as FASN, HIF-1α facilitates lipid accumulation in hepatocytes, thereby exacerbating MASLD progression (Luo et al., 2023; Ezzeddini et al., 2019). Beyond HIF-1α, accumulating evidence suggests that HIF-2α can also shape hepatic lipid handling and disease progression, and its effects may differ from (or even counterbalance) HIF-1α depending on the cell type and disease context (Mendoza et al., 2023; Hsu et al., 2020; Yang R. et al., 2025).
HIF-1α and HIF-2α are activated by hypoxic stress but they often drive distinct, and sometimes divergent, gene programs in the liver. In hepatocytes, HIF-2α has been repeatedly linked to lipid accumulation and inflammatory injury. Genetic investigations of Vhl-deficient hepatocytes suggest that steatosis, inflammation, and fibrotic remodeling are predominantly dependent on HIF-2α. Furthermore, the targeted deletion of HIF-2α in hepatocytes ameliorates fatty liver, parenchymal damage, lobular inflammation, and the advancement of fibrosis in dietary models of MASLD and MASH (Qu et al., 2011). By contrast, hepatocyte HIF-1α signaling is more consistently connected to fibrogenic pathways in MASLD, including mechanisms that favor collagen remodeling, while its impact on steatosis can vary across experimental settings (Mesarwi et al., 2016). From a therapeutic standpoint, HIF-2α is presently considered a more “drugged” target due to the clinical availability of small-molecule inhibitors. However, systemic blockade of HIF-2α frequently results in anemia (Dogra and Vaishampayan, 2025). Consequently, to optimize therapeutic efficacy and mitigate potential risks, it may be necessary to employ liver-targeted or cell-selective strategies for both isoforms.
HIFs not only aid metabolism but also affect liver immunity, crucial in MASLD progression (Takikawa et al., 2019). Here, the “immunometabolic” perspective is very helpful. The behavior of immune cells is closely related to how these cells use energy and nutrients, and these metabolic choices can directly affect inflammation and profibrotic functions (Kumar, 2019; Gilgenkrantz et al., 2021). In MASLD, especially MASH, HIF-1α partly drives chronic inflammation by influencing liver immune cells (Kou et al., 2023). Under hypoxia, HIFs trigger immune pathways that worsen inflammation and tissue damage, promoting fibrosis (Kou et al., 2023; Cai et al., 2021). A key effect of HIF-1α is altering macrophage polarization (Qiu et al., 2023). Hypoxia activates NF-κB, leading to pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, which recruit immune cells such as macrophages, neutrophils, and T cells, intensifying MASH’s inflammatory environment (Shao et al., 2025; Wang et al., 2022). HIF-1α also shifts macrophages from anti-inflammatory (M2) to pro-inflammatory (M1), exacerbating inflammation and fibrosis (Takikawa et al., 2019; Wang et al., 2022). Additionally, HIFs have been shown to directly influence the activation of hepatic stellate cells (HSCs), the key effector cells in liver fibrosis (Kou et al., 2023; Tuffs et al., 2025). Under hypoxic conditions, HIF-1α activates HSCs through the upregulation of TGF-β, a potent pro-fibrotic factor (Xu et al., 2024). The activation of HSCs leads to the secretion of extracellular matrix proteins, including collagen, which results in the accumulation of fibrotic tissue and liver stiffness (Kou et al., 2023; Xu et al., 2024). This process is central to the progression of MASLD into MASH and liver cirrhosis. This elucidates a biologically plausible “feed-forward” mechanism in advanced disease, in which hypoxia-induced HIF pathways promote inflammatory activation, while fibrogenesis further intensifies hypoxic stress.
HIFs’ metabolic and immune effects are interconnected, synergistically advancing MASLD. HIF-induced lipid buildup in hepatocytes releases danger-associated molecular patterns (DAMPs), activating immune cells and worsening metabolic issues, creating a cycle of liver damage and fibrosis (Pereira et al., 2023; Liang et al., 2024). Conversely, immune-derived cytokines and metabolic by-products can further reshape hepatocyte metabolism and HSC activation, strengthening a self-reinforcing loop that promotes progression from steatosis to MASH and fibrosis (Subramanian et al., 2022; Gao et al., 2022). This interplay emphasizes the complexity of MASLD and HIFs’ crucial role as disease modulators. In summary, HIFs exert significant influence over both metabolic and immune processes in the liver. By regulating key pathways involved in glucose and lipid metabolism, HIFs promote steatosis and insulin resistance, while simultaneously driving the inflammatory and fibrotic responses that underlie the progression to MASH and liver fibrosis (Wang et al., 2019; Gaucher et al., 2024). Understanding how HIFs coordinate these two processes is essential for developing targeted therapies aimed at halting the progression of MASLD and improving patient outcomes.
HIF-dependent immunometabolic programming of macrophages, neutrophils, and T cells in MASLD
Building on the well-documented tissue-level associations between hypoxia, HIF activation, inflammation, and fibrosis, this subsection seeks to explore a more focused question: how HIFs modulate the intracellular metabolism of key immune cells in MASLD, and how these metabolic changes impact inflammatory or pro-fibrotic responses. In steatotic and inflamed livers, immune cells often face low oxygen, excess lipids, and many cytokines (Ting, 2024). Under these conditions, HIF pathways can be activated by true hypoxia, and also by inflammation-related signals that mimic hypoxic responses (Ting, 2024). These signals influence which energy pathway immune cells rely on (Suzuki et al., 2016). Glycolysis breaks down glucose quickly and can support rapid inflammatory responses (Li HR. et al., 2025). Oxidative phosphorylation (OXPHOS) uses mitochondria to generate energy more efficiently but usually needs enough oxygen (Li HR. et al., 2025). Fatty acid oxidation (FAO) uses fatty acids as fuel and is often linked with longer-term functions and mitochondrial fitness (Leb et al., 2024).
In MASLD, macrophages consist of resident Kupffer cells and monocyte-derived macrophages, with their functions linked to their metabolic state (Drummer et al., 2023; Geric et al., 2018). Generally, inflammatory macrophages favor glycolysis, whereas restorative ones rely more on mitochondrial metabolism. Although not absolute, this pattern helps organize evidence (Geric et al., 2018). HIF-1α can push macrophages toward glycolysis by increasing the expression of glycolytic genes, including GLUT1, HK2, PFKFB3, and LDHA (Liu C. et al., 2023; Zhang et al., 2023). HIF-1α can also induce PDK1, which reduces pyruvate entry into the TCA cycle and can limit OXPHOS (Zhang et al., 2023). This shift is not only about energy supply. It can also affect cytokine output. For example, succinate accumulation can stabilize HIF-1α and promote IL-1β expression in activated macrophages (She et al., 2018). Pyruvate kinase M2 (PKM2) is another metabolic checkpoint that can support HIF-1α activity and IL-1β induction in inflammatory macrophages (Kang et al., 2025). In MASLD, these macrophage-derived cytokines and chemokines can worsen hepatocyte stress, attract more immune cells, and support stellate cell activation, which together can promote inflammation and fibrosis (Wang et al., 2021). Macrophages in MASLD are diverse, with some states being beneficial (Shi et al., 2025). In MASH models, TREM2-linked lipid-associated macrophages aid tissue remodeling and are crucial for fibrosis resolution during disease regression (Shi et al., 2025). This indicates that macrophage metabolism can promote repair in specific contexts (Shi et al., 2025). Thus, the main concern is whether HIF-driven metabolic changes lead macrophages to cause ongoing injury or support balanced remodeling and resolution, depending on the disease stage.
Neutrophils can accumulate in MASH and contribute to injury through oxidants, proteases, and neutrophil extracellular traps (NETs) (Wu et al., 2020; Xu et al., 2026). Because neutrophils rely heavily on glycolysis, they can remain functional in low-oxygen areas, and hypoxia-related HIF-1α signaling has been shown to prolong neutrophil survival, which may increase their persistence in inflamed liver tissue (Morrison et al., 2023; Arelaki et al., 2022). In MASLD and MASH, reviews summarize growing evidence that NETs can amplify hepatic inflammation and may be linked with fibrotic progression, although the exact pathways differ across models (Xu et al., 2026; Yin J. et al., 2025; Yang X. et al., 2025; Du et al., 2022). T cell activation commonly involves increased glycolysis to support proliferation and cytokine production, and hypoxia can further bias these programs through HIF signaling (Nastasi et al., 2021). HIF-1α has been shown to promote Th17 programs while limiting Treg development, linking oxygen sensing to lineage decisions (Singh et al., 2016). In MASLD, Th17 and IL-17 related pathways have been associated with disease progression and fibrosis (Chackel et al., 2016).
In the context of MASLD, HIF pathways have the capacity to alter immune cell metabolism in macrophages, neutrophils, and T cells. A prevalent consequence of this alteration is an increased dependence on glycolysis and diminished mitochondrial flexibility, which can sustain chronic inflammatory signals and facilitate pro-fibrotic interactions with hepatic stellate cells. Concurrently, immune cell metabolic programs exhibit heterogeneity, with certain metabolic states potentially contributing to tissue repair and the resolution of fibrosis under specific conditions. Consequently, the study of immunometabolism offers a valuable framework for comprehending disease progression and identifying therapeutic targets, while emphasizing the importance of specificity regarding cell type and disease stage.
Challenges and limitations
Despite the significant progress made in understanding the role of HIFs in MASLD, several challenges and limitations remain in fully elucidating their function and translating this knowledge into therapeutic applications. These challenges are critical for the development of effective treatments and for advancing our understanding of the immunometabolic interplay in MASLD.
One of the key challenges in studying HIFs in MASLD lies in the complexity of HIF regulation. HIFs are regulated by multiple factors, including oxygen levels, but also metabolic signals, inflammatory mediators, and other stress conditions, which complicate their precise role in disease progression (Hsu et al., 2020; Haque and Kousoulas, 2019; Luo et al., 2025). The regulation of HIFs is further complicated by the presence of different isoforms (HIF-1α, HIF-2α, and HIF-3α), each of which may have distinct and sometimes opposing effects depending on the tissue context (Jiang et al., 2017; Zhou et al., 2025). In liver disease, these isoforms could have differential roles in metabolic regulation and immune response, which remains poorly understood (Morello et al., 2018). For instance, while HIF-1α is predominantly involved in regulating glycolysis and lipid metabolism, HIF-2α is linked to more specific tissue repair and regeneration processes, with conflicting outcomes depending on the disease stage (Novianti et al., 2019; Yu et al., 2020). This complexity complicates the development of therapies that target HIF pathways, as interventions may need to be isoform-specific and context-dependent.
Within the hepatic environment, HIFs influence a diverse array of cell types, including hepatocytes, HSCs, and immune cells, each exhibiting distinct responses to hypoxic stress (Wang et al., 2019; Kou et al., 2023). For instance, activation of HIF-1α in hepatocytes is associated with lipid accumulation and metabolic dysfunction, whereas its activation in HSCs is linked to the promotion of fibrosis (Luo et al., 2023). These tissue-specific responses complicate the understanding of how HIFs orchestrate various processes and pose challenges in selectively targeting specific cellular responses without disrupting other essential hepatic functions. Under hypoxic conditions, HIFs control metabolic changes like increased glycolysis and lipid buildup, as well as immune responses like pro-inflammatory cytokine activation and fibrosis pathways (Wang et al., 2019; Luo et al., 2023). The interaction between these processes is not well understood, but their dysregulation, where metabolism and inflammation fuel each other, may worsen disease progression. Clarifying how HIFs coordinate these responses is key to finding treatments for both metabolic and immune aspects of MASLD.
Therapeutic translation for chronic metabolic diseases like MASLD faces safety challenges. HIF pathways, which regulate angiogenesis and cell survival, could promote tumor growth, posing risks for MASLD patients prone to HCC (Chen et al., 2019b). Additionally, HIF’s influence on extra-hepatic metabolism could disrupt lipid and insulin regulation in other tissues (Laitakari et al., 2020; Xie et al., 2017). These concerns highlight the importance of liver-targeted delivery, cell-specific strategies, and thorough safety evaluations for HIF therapies in MASLD.
Perhaps one of the most significant limitations in the study of HIFs in MASLD is the lack of targeted therapies. While HIFs are attractive therapeutic targets, their complex regulation and tissue-specific actions make it challenging to develop drugs that specifically modulate HIF activity without causing undesirable side effects (Gonzalez et al., 2018). Current strategies targeting HIFs, such as HIF stabilizers, are still in the early stages of development, and there is a need for more precise and effective treatments (Laitakari et al., 2020). Moreover, given the multifactorial nature of MASLD, therapies aimed solely at modulating HIFs may not be sufficient, and combination therapies targeting multiple pathways may be required for successful treatment.
Future directions
As our understanding of the role of HIFs in MASLD deepens, several promising future directions have emerged. These directions focus on enhancing therapeutic efficacy, improving diagnostic approaches, and advancing experimental models to better reflect the complexity of human disease.
Future strategies for targeting HIFs in MASLD focus on precision delivery systems for therapies. The challenge is to target liver cells or specific HIF isoforms without affecting other tissues. Advances in nanotechnology and targeted delivery systems, like nanoparticle carriers or RNA-based therapies, offer solutions (Liu MX. et al., 2023). These systems can deliver HIF modulators directly to liver cells, ensuring precise action and reducing side effects (Liu MX. et al., 2023). They also allow controlled release in response to environmental cues, like hypoxia, enhancing efficacy and safety. Furthermore, chronic inflammation drives MASLD progression, especially in MASH (Cai et al., 2021). Future therapies could focus on resolving inflammation rather than just suppressing it (Xia et al., 2024). HIFs are key in immune regulation, and modulating HIF signaling might help resolve inflammation and prevent fibrosis (Xia et al., 2024).
Identifying non-invasive biomarkers for MASLD progression, especially for fibrosis or MASH, remains challenging (Lefere et al., 2017). Advances in genomics, proteomics, and metabolomics may help find biomarkers linked to HIF activation (Hagemann et al., 2022; He D. et al., 2021). Hypoxia-related biomarkers like lactate or specific cytokines could indicate early disease progression, reducing the need for liver biopsies (Bozyel et al., 2025). Imaging technologies could further aid in monitoring hypoxic liver areas, enabling real-time tracking of disease and treatment effects (A et al., 2021). To advance therapeutic development, more advanced preclinical models that accurately mimic human MASLD are needed. Current rodent models fall short in replicating the complexity of human liver disease, especially regarding immune-metabolic interactions and fibrosis. Developing sophisticated models like humanized mice or 3D liver organoids will enhance understanding of MASLD’s molecular mechanisms and aid in testing new therapies, offering more reliable data for clinical applications.
A significant unresolved issue in the field of MASLD immunometabolism is determining whether HIF-mediated metabolic reprogramming within specific immune cell subsets, such as macrophages and T cells, is essential for the progression from simple steatosis to inflammatory MASH and fibrogenesis, or if it primarily represents a secondary response to tissue stress (Morello et al., 2018; Mooli et al., 2021). To explore this subject comprehensively, it is imperative that optimal models are developed to (Chrysavgis et al., 2022): accurately represent physiological oxygen heterogeneity, including zonation-like gradients and controlled hypoxic conditions (Zhong et al., 2024); incorporate multicellular interactions among hepatocytes, stellate cells, endothelial cells, and well-defined immune populations (Wang et al., 2025); enable longitudinal monitoring of transitions between various disease stages; and provide quantitative evaluations of metabolic activity, such as extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) measurements, isotope tracing, and single-cell or spatial profiling (Pereira et al., 2023; Hoogerland et al., 2022). Furthermore, in vivo studies utilizing inducible, cell-specific perturbations of HIF-1α and HIF-2α at different disease stages will be essential (Wang et al., 2019).
Discussion
The role of HIFs in the pathogenesis of MASLD is complex and multifaceted, influencing both metabolic and immune pathways. HIFs are central to the progression of MASLD, driving metabolic dysregulation, lipid accumulation, insulin resistance, and chronic inflammation. Their ability to modulate hepatic metabolism and immune responses places them at the crossroads of the disease’s pathophysiology, making them attractive targets for therapeutic intervention.
Despite the promising potential of HIF-targeted therapies, significant challenges remain. The complexity of HIF regulation, tissue-specific effects, and the dysregulated crosstalk between metabolic and immune pathways complicate the development of precise and effective treatments. Furthermore, the lack of non-invasive biomarkers for disease progression and the need for more advanced preclinical models hinder progress in translating these findings into clinical practice.
Looking ahead, precision medicine approaches, such as targeted delivery systems and therapies aimed at resolving inflammation, offer hope for more effective treatments. Additionally, advances in non-invasive biomarkers and preclinical models will improve our ability to monitor and treat MASLD more accurately. By overcoming these challenges, we can better understand the intricate role of HIFs in MASLD and develop more personalized, effective therapeutic strategies, ultimately improving patient outcomes.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author contributions
YZ: Data curation, Project administration, Investigation, Writing – review and editing, Conceptualization, Writing – original draft, Supervision. YW: Supervision, Writing – review and editing, Investigation, Writing – original draft, Project administration. FL: Writing – original draft, Writing – review and editing. GY: Writing – review and editing, Writing – original draft.
Acknowledgements
The Figure 1 (ID: TOYSO44245) and Figure 2 (ID: IWOTWa98a7) were created by Figdraw.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesAjmeraV.LoombaR. (2021). Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol. Metab.50, 101167. 10.1016/j.molmet.2021.10116733460786ArelakiS.KoletsaT.SinakosE.PapadopoulosV.ArvanitakisK.SkendrosP. (2022). Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis. Virchows Arch.481 (3), 455–465. 10.1007/s00428-022-03330-735503185AsaiY.YamadaT.TsukitaS.TakahashiK.MaekawaM.HonmaM. (2017). Activation of the hypoxia inducible factor 1α subunit pathway in steatotic liver contributes to formation of cholesterol gallstones. Gastroenterology152 (6), 1521–1535.e8. 10.1053/j.gastro.2017.01.00128088462BasheeruddinM.QausainS. (2024). Hypoxia-inducible factor 1-Alpha (HIF-1α): an essential regulator in cellular metabolic control. Cureus16 (7), e63852. 10.7759/cureus.6385239099978BozyelB.DoğanÖ.ElgünS.ÖzdemirB. (2025). Hypoxic responses in periodontal tissues: influence of smoking and periodontitis. J. Clin. Periodontol.52 (2), 249–257. 10.1111/jcpe.1408739491490CaiH.BaiZ.GeR. L. (2021). Hypoxia-inducible factor-2 promotes liver fibrosis in non-alcoholic steatohepatitis liver disease via the NF-κB signalling pathway. Biochem. Biophys. Res. Commun.540, 67–74. 10.1016/j.bbrc.2021.01.00233450482ChackeleviciusC. M.GambaroS. E.TiribelliC.RossoN. (2016). Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J. Gastroenterol.22 (41), 9096–9103. 10.3748/wjg.v22.i41.909627895397ChenJ.ChenJ.FuH.LiY.WangL.LuoS. (2019a). Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway. Am. J. Physiol. Endocrinol. Metab.317 (4), E710–e722. 10.1152/ajpendo.00052.201931430204ChenJ.ChenJ.HuangJ.LiZ.GongY.ZouB. (2019b). HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. Aging (Albany NY)11 (23), 10839–10860. 10.18632/aging.10248831796646ChenY.LiuL.XiaL.WuN.WangY.LiH. (2022). TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation. J. Exp. Clin. Cancer Res.41 (1), 44. 10.1186/s13046-022-02252-135101076ChrysavgisL.GiannakodimosI.DiamantopoulouP.CholongitasE. (2022). Non-alcoholic fatty liver disease and hepatocellular carcinoma: clinical challenges of an intriguing link. World J. Gastroenterol.28 (3), 310–331. 10.3748/wjg.v28.i3.31035110952CianciN.SubhaniM.HillT.KhannaA.ZhengD.ShethA. (2022). Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: a systematic review and meta-analysis. World J. Hepatol.14 (5), 1025–1037. 10.4254/wjh.v14.i5.102535721296CuiY.GuoC.XiaZ.XueY.SongB.HuW. (2023). Exploring the therapeutic potential of a nano micelle containing a carbon monoxide-releasing molecule for metabolic-associated fatty liver disease by modulating hypoxia-inducible factor-1α. Acta Biomater.169, 500–516. 10.1016/j.actbio.2023.08.00937574157DanfordC. J.YaoZ. M.JiangZ. G. (2018). Non-alcoholic fatty liver disease: a narrative review of genetics. J. Biomed. Res.32 (5), 389–400. 10.7555/JBR.32.2018004530355853DavisA.MorrisK. V.ShevchenkoG. (2022). Hypoxia-directed tumor targeting of CRISPR-Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles. Mol. Ther. Methods Clin. Dev.25, 158–169. 10.1016/j.omtm.2022.03.00835402634Del Río-MorenoM.Alors-PérezE.González-RubioS.FerrínG.ReyesO.Rodríguez-PerálvarezM. (2019). Dysregulation of the splicing machinery is associated to the development of nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab.104 (8), 3389–3402. 10.1210/jc.2019-0002130901032DograR.VaishampayanU. (2025). Hypoxia inducible Factor-2α (HIF-2α) Pathway inhibitors. J. Kidney Cancer VHL12 (3), 1–15. 10.15586/jkc.v12i3.41340620865DongX.SuX.YuJ.LiuJ.ShiX.PanQ. (2017). Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex. J. Mol. Graph Model71, 116–123. 10.1016/j.jmgm.2016.11.01127902963DrummerCtSaaoudF.JhalaN. C.CuetoR.SunY.XuK. (2023). Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages. Front. Immunol.14, 1113883. 10.3389/fimmu.2023.111388336776889DuJ.ZhangJ.ChenX.ZhangS.ZhangC.LiuH. (2022). Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients. Clin. Res. Hepatol. Gastroenterol.46 (1), 101697. 10.1016/j.clinre.2021.10169733848669EzzeddiniR.TaghikhaniM.SomiM. H.SamadiN.RasaeeM. J. (2019). Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma. Life Sci.224, 169–176. 10.1016/j.lfs.2019.03.05630914315GaoH.JinZ.BandyopadhyayG.WangG.ZhangD.RochaK. C. E. (2022). Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis. Cell Metab.34 (8), 1201–1213.e5. 10.1016/j.cmet.2022.07.00635921818GaucherJ.MontellierE.VialG.ChuffartF.GuellerinM.BouyonS. (2024). Long-term intermittent hypoxia in mice induces inflammatory pathways implicated in sleep apnea and steatohepatitis in humans. iScience27 (2), 108837. 10.1016/j.isci.2024.10883738303705GericI.TyurinaY. Y.KryskoO.KryskoD. V.De SchryverE.KaganV. E. (2018). Lipid homeostasis and inflammatory activation are disturbed in classically activated macrophages with peroxisomal β-oxidation deficiency. Immunology153 (3), 342–356. 10.1111/imm.1284428940384GilgenkrantzH.MallatA.MoreauR.LotersztajnS. (2021). Targeting cell-intrinsic metabolism for antifibrotic therapy. J. Hepatol.74 (6), 1442–1454. 10.1016/j.jhep.2021.02.01233631228GonzalezF. J.XieC.JiangC. (2018). The role of hypoxia-inducible factors in metabolic diseases. Nat. Rev. Endocrinol.15 (1), 21–32. 10.1038/s41574-018-0096-z30275460HagemannC. A.LegartC.MøllerhøjM. B.MadsenM. R.HansenH. H.KønigM. J. (2022). A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. PLoS One17 (10), e0275901. 10.1371/journal.pone.027590136260611HanJ.HeY.ZhaoH.XuX. (2019). Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway. J. Cell Biochem.120 (9), 14735–14744. 10.1002/jcb.2873431009107HanH. J.SaeidiS.KimS. J.PiaoJ. Y.LimS.Guillen-QuispeY. N. (2021). Alternative regulation of HIF-1α stability through Phosphorylation on Ser451. Biochem. Biophys. Res. Commun.545, 150–156. 10.1016/j.bbrc.2021.01.04733550096HaqueM.KousoulasK. G. (2019). The kaposi's sarcoma-associated herpesvirus ORF34 protein interacts and stabilizes HIF-2α via binding to the HIF-2α bHLH and PAS domains. J. Virol.93 (17). 10.1128/JVI.00764-1931189709HeY.YangW.GanL.LiuS.NiQ.BiY. (2021a). Silencing HIF-1α aggravates non-alcoholic fatty liver disease in vitro through inhibiting PPAR-α/ANGPTL4 singling pathway. Gastroenterol. Hepatol.44 (5), 355–365. 10.1016/j.gastrohep.2020.09.01433272734HeD.SuY.MengD.WangX.WangJ.YeH. (2021b). A pilot study optimizing metabolomic and lipidomic acquisition in serum for biomarker discovery in nonalcoholic fatty liver disease. J. Mass Spectrom. Adv. Clin. Lab.22, 17–25. 10.1016/j.jmsacl.2021.10.00134939051HolznerL. M. W.MurrayA. J. (2021). Hypoxia-Inducible factors as key players in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Front. Med. (Lausanne)8, 753268. 10.3389/fmed.2021.75326834692739HoogerlandJ. A.StaelsB.DombrowiczD. (2022). Immune-metabolic interactions in homeostasis and the progression to NASH. Trends Endocrinol. Metab.33 (10), 690–709. 10.1016/j.tem.2022.07.00135961913HsuT. S.LinY. L.WangY. A.MoS. T.ChiP. Y.LaiA. C. (2020). HIF-2α is indispensable for regulatory T cell function. Nat. Commun.11 (1), 5005. 10.1038/s41467-020-18731-y33024109IsazaS. C.Del Pozo-MarotoE.Domínguez-AlcónL.ElbouayadiL.González-RodríguezÁ.García-MonzónC. (2020). Hypoxia and non-alcoholic fatty liver disease. Front. Med. (Lausanne)7, 578001. 10.3389/fmed.2020.57800133195326JiangL.ShiS.ShiQ.ZhangH.HuR.WangM. (2017). Similarity in the functions of HIF-1α and HIF-2α proteins in cervical cancer cells. Oncol. Lett.14 (5), 5643–5651. 10.3892/ol.2017.683729098039KangZ.XieR.CuiY.ChenZ.LiJ.LvJ. (2025). Macrophage PKM2 depletion ameliorates hepatic inflammation and acute liver injury in mice. Front. Pharmacol.16, 1546045. 10.3389/fphar.2025.154604540351417KempińskiR.ŁukawskaA.KrzyżanowskiF.ŚlósarzD.PoniewierkaE. (2019). Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study. Adv. Clin. Exp. Med.28 (12), 1615–1620. 10.17219/acem/10617331025557KouK.LiS.QiuW.FanZ.LiM.LvG. (2023). Hypoxia-inducible factor 1α/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis. Biochem. Biophys. Res. Commun.653, 21–30. 10.1016/j.bbrc.2023.02.03236848821KumarV. (2019). Inflammation research sails through the sea of immunology to reach immunometabolism. Int. Immunopharmacol.73, 128–145. 10.1016/j.intimp.2019.05.00231096130LaitakariA.TapioJ.MäkeläK. A.HerzigK. H.DenglerF.GyllingH. (2020). HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD. J. Mol. Med. Berl.98 (5), 719–731. 10.1007/s00109-020-01903-032296880LeblancP. O.BourgoinS. G.PoubelleP. E.TessierP. A.PelletierM. (2024). Metabolic regulation of neutrophil functions in homeostasis and diseases. J. Leukoc. Biol.116 (3), 456–468. 10.1093/jleuko/qiae02538452242LefereS.Van SteenkisteC.VerhelstX.Van VlierbergheH.DevisscherL.GeertsA. (2016). Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease. Cell Mol. Life Sci.73 (18), 3419–3431. 10.1007/s00018-016-2222-127091156LefereS.Van de VeldeF.DevisscherL.BekaertM.RaevensS.VerhelstX. (2017). Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int. J. Obes. (Lond).41 (8), 1207–1213. 10.1038/ijo.2017.10228461687LiN.LiY.LiZ.HuangC.YangY.LangM. (2016). Hypoxia inducible factor 1 (HIF-1) recruits macrophage to activate pancreatic stellate cells in pancreatic ductal adenocarcinoma. Int. J. Mol. Sci.17 (6). 10.3390/ijms1706079927271610LiY.YangX.ChenZ.DongW.ChenX.WangW. (2025a). Moderate intensity continuous training mitigates hypertension-induced renal fibrosis by inhibiting HIF-1α-mediated autophagy. Front. Physiol.16, 1529811. 10.3389/fphys.2025.152981140213150LiH. R.XiongJ.WangC. H.HuL. B.WangY. B.PingQ. R. (2025b). CAR-T cell therapy for solid tumors: HIF-1α as a potential enhancement strategy. Autoimmunity58 (1), 2579069. 10.1080/08916934.2025.257906941255058LiangY.ZhangR.BiswasS.BuQ.XuZ.QiaoL. (2024). Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma. Cell Prolif.57 (4), e13576. 10.1111/cpr.1357637994257LiuZ.WuZ.FanY.FangY. (2020). An overview of biological research on hypoxia-inducible factors (HIFs). Endokrynol. Pol.71 (5), 432–440. 10.5603/EP.a2020.006433202030LiuC.LiS.ZhangX.JinC.ZhaoB.LiL. (2023a). Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway. Cancer Gene Ther.30 (5), 647–658. 10.1038/s41417-022-00542-636241702LiuM. X.XuL.CaiY. T.WangR. J.GuY. Y.LiuY. C. (2023b). Carbon nitride-based siRNA vectors with self-produced O(2) effects for targeting combination therapy of liver fibrosis via HIF-1α-Mediated TGF-β1/Smad pathway. Adv. Healthc. Mater12 (29), e2301485. 10.1002/adhm.20230148537463681LuoM.LiT.SangH. (2023). The role of hypoxia-inducible factor 1α in hepatic lipid metabolism. J. Mol. Med. Berl.101 (5), 487–500. 10.1007/s00109-023-02308-536973503LuoS.LuZ.WangL.LiY.ZengY.LuH. (2025). Hepatocyte HIF-2α aggravates NAFLD by inducing ferroptosis through increasing extracellular iron. Am. J. Physiol. Endocrinol. Metab.328 (1), E92–e104. 10.1152/ajpendo.00287.202339679942MendozaS. V.GenetosD. C.YellowleyC. E. (2023). Hypoxia-inducible Factor-2α signaling in the skeletal System. JBMR Plus7 (4), e10733. 10.1002/jbm4.1073337065626MesarwiO. A.ShinM. K.Bevans-FontiS.SchlesingerC.ShawJ.PolotskyV. Y. (2016). Hepatocyte Hypoxia inducible Factor-1 mediates the development of liver Fibrosis in a mouse model of Nonalcoholic fatty liver disease. PLoS One11 (12), e0168572. 10.1371/journal.pone.016857228030556MesarwiO. A.MoyaE. A.ZhenX.GautaneM.ZhaoH.Wegbrans GiróP. (2021). Hepatocyte HIF-1 and intermittent hypoxia independently impact liver fibrosis in murine nonalcoholic fatty liver disease. Am. J. Respir. Cell Mol. Biol.65 (4), 390–402. 10.1165/rcmb.2020-0492OC34003729MesquitaI.FerreiraC.MoreiraD.KluckG. E. G.BarbosaA. M.TorradoE. (2020). The absence of HIF-1α increases susceptibility to Leishmania donovani infection via activation of BNIP3/mTOR/SREBP-1c axis. Cell Rep.30 (12), 4052–4064.e7. 10.1016/j.celrep.2020.02.09832209468MooliR. G. R.RodriguezJ.TakahashiS.SolankiS.GonzalezF. J.RamakrishnanS. K. (2021). Hypoxia via ERK signaling inhibits hepatic PPARα to promote fatty liver. Cell Mol. Gastroenterol. Hepatol.12 (2), 585–597. 10.1016/j.jcmgh.2021.03.01133798787MorelloE.SuttiS.FogliaB.NovoE.CannitoS.BoccaC. (2018). Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. Hepatology67 (6), 2196–2214. 10.1002/hep.2975429266399MorrisonT.WattsE. R.SadikuP.WalmsleyS. R. (2023). The emerging role for metabolism in fueling neutrophilic inflammation. Immunol. Rev.314 (1), 427–441. 10.1111/imr.1315736326284NastasiC.Willerlev-OlsenA.DalhoffK.FordS. L.GadsbøllA.BuusT. B. (2021). Inhibition of succinate dehydrogenase activity impairs human T cell activation and function. Sci. Rep.11 (1), 1458. 10.1038/s41598-020-80933-733446766NoviantiT.JuniantitoV.JusufA. A.AridaE. A.JusmanS. W. A.SadikinM. (2019). Expression and role of HIF-1α and HIF-2α in tissue regeneration: a study of hypoxia in house gecko tail regeneration. Organogenesis15 (3), 69–84. 10.1080/15476278.2019.164488931409194OrlandoI. M. C.LafleurV. N.StortiF.SpielmannP.CrowtherL.SantambrogioS. (2020). Distal and proximal hypoxia response elements cooperate to regulate organ-specific erythropoietin gene expression. Haematologica105 (12), 2774–2784. 10.3324/haematol.2019.23640631857363PackerM. (2020). Mutual antagonism of hypoxia-inducible factor isoforms in cardiac, vascular, and renal disorders. JACC Basic Transl. Sci.5 (9), 961–968. 10.1016/j.jacbts.2020.05.00633015417PereiraE.AraujoB. P.RodriguesK. L.SilvaresR. R.GuimarãesF. V.MartinsC. S. M. (2023). Cholesterol exacerbates the pathophysiology of non-alcoholic steatohepatitis by upregulating hypoxia-inducible factor 1 and modulating microcirculatory dysfunction. Nutrients15 (24), 5034. 10.3390/nu1524503438140293PowellE. E.WongV. W.RinellaM. (2021). Non-alcoholic fatty liver disease. Lancet.397 (10290), 2212–2224. 10.1016/S0140-6736(20)32511-333894145QiuB.YuanP.DuX.JinH.DuJ.HuangY. (2023). Hypoxia inducible factor-1α is an important regulator of macrophage biology. Heliyon9 (6), e17167. 10.1016/j.heliyon.2023.e1716737484306QuA.TaylorM.XueX.MatsubaraT.MetzgerD.ChambonP. (2011). Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology54 (2), 472–483. 10.1002/hep.2440021538443RiopelM.MoonJ. S.BandyopadhyayG. K.YouS.LamK.LiuX. (2020). Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism. Mol. Metab.41, 101039. 10.1016/j.molmet.2020.10103932534258ShaoL.WangQ.ChenB.ZhengY. (2025). The roles and molecular mechanisms of HIF-1α in pulpitis. J. Dent. Res.104 (7), 715–724. 10.1177/0022034525132097040102725SheL.XuD.WangZ.ZhangY.WeiQ.AaJ. (2018). Curcumin inhibits hepatic stellate cell activation via suppression of succinate-associated HIF-1α induction. Mol. Cell Endocrinol.476, 129–138. 10.1016/j.mce.2018.05.00229746885ShiS.ZhouY.ZhangH.ZhangJ. (2025). TREM2 in MASH: integrating lipid metabolism and immune response. Front. Immunol.16, 1604837. 10.3389/fimmu.2025.160483740636122ShinG. C.LeeH. M.KimN.YooS. K.ParkH. S.ChoiL. S. (2022). Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation. Sci. Rep.12 (1), 21483. 10.1038/s41598-022-25802-136509805SinghY.ShiX.ZhangS.UmbachA. T.ChenH.SalkerM. S. (2016). Prolyl hydroxylase 3 (PHD3) expression augments the development of regulatory T cells. Mol. Immunol.76, 7–12. 10.1016/j.molimm.2016.06.00327331863SubramanianP.HampeJ.TackeF.ChavakisT. (2022). Fibrogenic pathways in metabolic dysfunction associated fatty liver disease (MAFLD). Int. J. Mol. Sci.23 (13), 6996. 10.3390/ijms2313699635805998SundaramS. S.HalbowerA.PanZ.RobbinsK.CapocelliK. E.KlawitterJ. (2016). Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J. Hepatol.65 (3), 560–569. 10.1016/j.jhep.2016.04.01027501738SuzukiH.HisamatsuT.ChibaS.MoriK.KitazumeM. T.ShimamuraK. (2016). Glycolytic pathway affects differentiation of human monocytes to regulatory macrophages. Immunol. Lett.176, 18–27. 10.1016/j.imlet.2016.05.00927208804TakikawaA.UsuiI.FujisakaS.TsuneyamaK.OkabeK.NakagawaT. (2019). Macrophage-specific hypoxia-inducible factor-1α deletion suppresses the development of liver tumors in high-fat diet-fed obese and diabetic mice. J. Diabetes Investig.10 (6), 1411–1418. 10.1111/jdi.1304730897274TingK. K. Y. (2024). Revisiting the role of hypoxia-inducible factors and nuclear factor erythroid 2-related factor 2 in regulating macrophage inflammation and metabolism. Front. Cell Infect. Microbiol.14, 1403915. 10.3389/fcimb.2024.140391539119289TiroshO. (2018). Hypoxic signaling and cholesterol lipotoxicity in fatty liver disease progression. Oxid. Med. Cell Longev.2018, 2548154. 10.1155/2018/254815429955245TuffsC.DupovacM.RichterK.HoltenS.SchaschingerT.MargO. (2025). Genetic loss of HIF-Prolyl-Hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis. Am. J. Pathol.195 (3), 480–493. 10.1016/j.ajpath.2024.10.01839566823van der GraaffD.KwantenW. J.FrancqueS. M. (2019). The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med. Hypotheses122, 188–197. 10.1016/j.mehy.2018.11.01430593409VitaT.MurphyD. J.OsborneM. T.BajajN. S.KeraliyaA.JacobS. (2019). Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET/CT. Radiology291 (2), 330–337. 10.1148/radiol.201918179330835188WangX.de Carvalho RibeiroM.Iracheta-VellveA.LoweP.AmbadeA.SatishchandranA. (2019). Macrophage-specific hypoxia-inducible Factor-1α contributes to impaired autophagic flux in nonalcoholic steatohepatitis. Hepatology69 (2), 545–563. 10.1002/hep.3021530102772WangC. H.LiuH. M.ChangZ. Y.HuangT. H.LeeT. Y. (2021). Losartan prevents hepatic steatosis and macrophage polarization by inhibiting HIF-1α in a murine model of NAFLD. Int. J. Mol. Sci.22 (15), 7841. 10.3390/ijms2215784134360607WangX.DuH.LiX. (2022). Artesunate attenuates atherosclerosis by inhibiting macrophage M1-like polarization and improving metabolism. Int. Immunopharmacol.102, 108413. 10.1016/j.intimp.2021.10841334891003WangS.LiuX.HeJ.CuiY.JiaA. (2025). Serum metabolites and gut microbiota mediate the causal link between anxiety and nonalcoholic fatty liver disease: a Mendelian randomization analysis. Eur. J. Gastroenterol. Hepatol.37 (12), 1370–1379. 10.1097/MEG.000000000000304340900524WuL.GaoX.GuoQ.LiJ.YaoJ.YanK. (2020). The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise. Hepatol. Int.14 (5), 652–666. 10.1007/s12072-020-10081-732880077XiaJ.ChenH.WangX.ChenW.LinJ.XuF. (2024). Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α. Nat. Commun.15 (1), 4755. 10.1038/s41467-024-48954-238834568XieC.YagaiT.LuoY.LiangX.ChenT.WangQ. (2017). Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat. Med.23 (11), 1298–1308. 10.1038/nm.441229035368XiongS.LiuZ.YaoJ.HuangS.DingX.YuH. (2025). HIF-1α regulated GLUT1-mediated glycolysis enhances treponema pallidum-induced cytokine responses. Cell Commun. Signal23 (1), 219. 10.1186/s12964-025-02211-140346557XuM.WarnerC.DuanX.ChengZ.JeyarajanA. J.LiW. (2024). HIV coinfection exacerbates HBV-Induced liver fibrogenesis through a HIF-1α- and TGF-β1-dependent pathway. J. Hepatol.80 (6), 868–881. 10.1016/j.jhep.2024.01.02638311121XuM.XuH.LingY. W.LiuJ. J.SongP.FangZ. Q. (2026). Neutrophil extracellular traps-triggered hepatocellular senescence exacerbates lipotoxicity in non-alcoholic steatohepatitis. J. Adv. Res.79, 521–534. 10.1016/j.jare.2025.03.01540068761YanR.CaiH.ZhouX.BaoG.BaiZ.GeR. L. (2024). Hypoxia-inducible factor-2α promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells. Front. Endocrinol. (Lausanne)15, 1344971. 10.3389/fendo.2024.134497138501098YangR.LiuW.ZhouY.ChengB.LiuS.WuR. (2025a). Modulating HIF-1α/HIF-2α homeostasis with shen-qi-huo-xue formula alleviates tubular ferroptosis and epithelial-mesenchymal transition in diabetic kidney disease. J. Ethnopharmacol.343, 119478. 10.1016/j.jep.2025.11947839947365YangX.GuoC.YangY.HuangL.LuoL.ZhouY. (2025b). Targeting neutrophil extracellular traps: SERPINE1 and THBS1 as non-invasive biomarkers for early detection of liver fibrosis in metabolic dysfunction-associated steatotic liver disease. Int. Immunopharmacol.158, 114828. 10.1016/j.intimp.2025.11482840349409YiX.QiM.HuangM.ZhouS.XiongJ. (2022). Honokiol inhibits HIF-1α-Mediated glycolysis to halt breast cancer growth. Front. Pharmacol.13, 796763. 10.3389/fphar.2022.79676335350760YinG.LiangH.ChengY.ChenS.ZhangX.MengD. (2025a). Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammation. Chem. Biol. Interact.405, 111306. 10.1016/j.cbi.2024.11130639536891YinJ.ZhuY.LiuR.WangW.WangZ.WangJ. (2025b). A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease. Front. Immunol.16, 1599956. 10.3389/fimmu.2025.159995640655142YuL.WangH.HanX.LiuH.ZhuD.FengW. (2020). Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α. J. Endocrinol.246 (1), 57–67. 10.1530/JOE-19-055532369776ZhangJ.YuanZ.LiX.WangF.WeiX.KangY. (2023). Activation of the JNK/COX-2/HIF-1α axis promotes M1 macrophage via glycolytic shift in HIV-1 infection. Life Sci. Alliance6 (12), e202302148. 10.26508/lsa.20230214837798121ZhongH.DongJ.ZhuL.MaoJ.DongJ.ZhaoY. (2024). Non-alcoholic fatty liver disease: pathogenesis and models. Am. J. Transl. Res.16 (2), 387–399. 10.62347/KMSA598338463579ZhouZ.WangM.ZhangX.XuY.LiP.ZhengZ. (2025). Synergistic potential of berberine and wogonin improved adipose inflammation and insulin resistance associated with obesity through HIF-α axis. Chin. Med.20 (1), 155. 10.1186/s13020-025-01223-w41039626ZhuB.WuY.HuangS.ZhangR.SonY. M.LiC. (2021). Uncoupling of macrophage inflammation from self-renewal modulates host recovery from respiratory viral infection. Immunity54 (6), 1200–1218.e9. 10.1016/j.immuni.2021.04.00133951416ZuoG.LiM.GuoX.WangL.YaoY.HuangJ. A. (2025). Fu brick tea supplementation ameliorates non-alcoholic fatty liver disease and associated endotoxemia via maintaining intestinal homeostasis and remodeling hepatic immune microenvironment. Food Res. Int.209, 116207. 10.1016/j.foodres.2025.11620740253128
Edited by:Sonia Michael Najjar, Ohio University, United States
Reviewed by:Yong Zhu, Anhui Medical University, China